Home About us Current issue Back issues Submission Instructions Advertise Contact Reader Login  

Search Article 
Advanced search 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 2070 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 
Export selected to
Reference Manager
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   1999| January-March  | Volume 10 | Issue 1  
    Online since January 17, 2008

  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
Fatal Complication of Percutaneous Femoral Vein Catheterization in a Hemodialysis Patient
Mohammed Al-Homrany, Mahmoud Wali, Saeed Abu-Eshy, Mohammed El-Tawail, Abdul Majeed Al-Taher
January-March 1999, 10(1):59-63
Percutaneous femoral vein catheterization is a safe procedure to perform and major complications are rarely reported. WE present a case of death following such procedure in a chronic hemodialysis patient. This case is to emphasize the importance of taking utmost care during insertion of he catheter and not to underestimate the dangers of what may look like a minor tear in the vein when surgical exploration is needed.
  9,330 473 -
The role of α1 -antitrypsin Deficiency in the Pathogenesis of Antineutrophil Cytoplasmic Antibodies Associated Systemic Necrotizing Vasculitides
Abdul-Nasser Alzouki
January-March 1999, 10(1):41-53
Alpha1-antitrypsin (D,1AT) is the most abundant circulating protease inhibitor (Pi) in human plasma. It has central function in controlling tissue degradation by inhibiting a large number of proteases including neutrophil elastase and proteinase 3 (PR3). PR3, the Wegner's autoantigen, has been suggested to be involved in the pathogenesis of small­vessel systemic vasculitides. α1 AT deficiency (PiZ) is frequent in Caucasian populations, and its homozygous state (PiZZ) is known to predispose to lung emphysema and chronic liver disease. A strong correlation between heterozygous (PiZ) and homozygous (PiZZ) α1 AT deficiency and anti-neutrophil cytoplasmic autoantibodies (ANCA) associated systemic nocrotizing vasculitides has recently been reported in various populations. In this review the pathogenesis of small-vessel vasculitides is outlined, focusing on the role of α1 AT deficiency. α1 AT has been suggested to have a crucial role as a protective protein in ANCA-associated vasculitic syndromes.
  5,655 424 -
Autosomal Dominant Polycystic Kidney Disease
Vedat Schwenger, Martin Zeier
January-March 1999, 10(1):7-20
  5,519 438 -
Urological complications of Cadaveric Renal Transplantation
Mohammad T Said, Mohammed S Abomelha, Ketab E Al Otaibi, Saad A Orkubi, Mohammad A Kourah, Atallah A Shaaban
January-March 1999, 10(1):36-40
Urological complications in 211 consecutive primary and secondary cadaveric renal transplants, performed t our institution between March 1993 and December 1996, were encountered in 13 patients (6.2%). The complications included urine leakage in four cases (1.9%)., obstruction of the upper urinary tract in seven (3.3%), urethral strictures in two (1%) and stone formation in one. Successfully treated complications amounted to 86%. Associated infection and urinary leak resulted in the loss of two grafts.
  2,972 328 -
Alport Syndrome: A Specific Case of Hereditary Nephropathy
Eric P Cohan
January-March 1999, 10(1):1-6
  2,729 357 -
Renal Replacement Therapy in Jordan
Riyad Said
January-March 1999, 10(1):64-65
  2,493 349 -
The Impact of Hepatitis C Infection and Antiviral Therapy on clinical Outcome in Renal Transplantation Recipients
Awad Rashid, Omar Abboud, Saad Al-Kaabi, Mustafa Taha, Adel Ashour, Mohamed El-Sayed
January-March 1999, 10(1):31-35
Hepatitis C viral infection (HCV) is presently a major problem in renal transplant recipients (RTR) with a high risk of chronicity resulting in liver cirrhosis. We screened 120 RTR (50 live related, 53 live unrelated, and 17 cadaveric); mean age of 45.2 years and mean post-transplant period of 6.8 years. Positive HCV antibodies using RIBA-2 test were detected in 43 patients (35.8%). Polymerase chain reaction was performed on 37 seropositive patients and confirmed viremia in 100% of hem. Forty-one seropositive patients (95.3%) had previous dialysis prior to transplantation; a mean of 4.5 years. Liver disease manifested in only five (11.6%) of the seropositive patients and hypertransaminasemia was detected in 14 (32.6%). Twelve seropositive patients with elevated transaminase levels and/or clinical evidence of liver disease, who all had positive PCR, underwent liver biopsy. Inflammation restricted to portal area was noticed in two, persistent hepatitis in three, chronic active hepatitis in four and cirrhosis in three. There was significantly higher incidence (P<0.03) of acute graft rejection in the seropositive (23.3%) compared to the seronegative patients (9.1% ). While the difference did not amount to statistical significance for chronic rejection (9.3% and 6.5% respectively). Two patients had acute cellular rejection related to interferon therapy. The leading cause of death was related to liver failure in the seropositive patients and coronary artery disease in he seronegative RTR. In conclusion, there is high incidence of HCV in or renal transplant recipients associated with relatively high morbidity and mortality. At present we are lacking an efficient and well­tolerated antiviral drug.
  2,433 367 -
Maintenance Intravenous Iron Therapy in Hepmodialysis Patients Receiving Recombinant Human Erythropoientin
Saleh Abu Romeh, Sameer Huraib, Noeline Murray, Danlami Tanimu, Ahmed Flaiw, Asmir Iqbal, Ghormullah Al Ghamdi, Khaja Quadri
January-March 1999, 10(1):21-25
Iron Supplementation is crucial in raising hematocrit as well as dosage saving for recombinant human erythropoietin therapy (rHuEPO) in maintenance hemodialysis patients. Intravenous iron has proved to be both safe and efficacious in this patient's population. However, the exact iron requirement has not been worked our. In this study we found that 1000 mg of element iron (given as iron saccharate) per moth was effective in maintaining hematocrit and hemoglobin at 33% and 110 gm/L respectively, and reducing the erythropoietin (EPO) dosage by about 20% in maintenance hemodialysis patients who were iron-replete. The serum ferritin increased from 219±144 to 320±234 µg/L (P<0.05). There were no major side effects and patients tolerated the monthly iron therapy well. Our study suggests that intravenous iron saccharate (100 mg/month) is effective and safe in patients on maintenance hemodialysis receiving RHUEPO.
  2,492 291 -
Synchronous Bilateral Lumbotomy in a Child with Bilateral Stone Disease and Renal Failure: An Old Operation Re-visited
JP Ward, M Zakaria, Zain Al Shareef
January-March 1999, 10(1):54-58
  2,346 316 -
Renal Replacement therapy in Morocco
Amal Bourquia
January-March 1999, 10(1):66-68
  2,204 314 -
Cyclosporine Neoral: A Local Experience
Mangalathillam R.N Nampoory, Kaivilayil V Johny, Jamal N Costandi, Rahim A Al-Muzaire, Ram K Gupta, Madhaven P Nair
January-March 1999, 10(1):26-30
Cyclosporine (CsA) is an effective immunosuppressant drug. Recently a new oral formulation, Sandimune Neoral (SIM-NOF) has been developed to overcome the problems of poor bioavailability, unpredictable blood levels and variable gastro-intestinal absorption seen with the use of traditional Cyclosporine, Sandimune (SIM). We conducted a prospective, open label crossover tolerability, efficacy and safety of SIM-NOF and (2) to compare SIM-NOF with SIM for their bioavailability, absorption pattern and consistence of 12-hour trough levels. Fourteen renal transplant recipients, with stable renal function (serum creatinine stable for more than six immediate previous months) and SIM dosages, were randomly selected for the study. Their age mean ± SD 38.2± 11.1 years, ad had completed 3.8± 2.2 years after transplantation. All patients were on triple drug immunosuppression with prednisone, azathioprine and SIM. The study consisted of an initial 12-week period, where SIM was used and cyclosporine 12-hour trough levels were monitored t least every four weeks. This was followed by a run-in period of two weeks, where a 12-hour cyclosporine profiling was done while patients were on SIM. This was followed by a 12-week period, Where SIM-NOF replaced SIM on a 1:1 dose conversion ratio. During this latter period, 12-hour trough levels (at 1,2,3,8 and 12 weeks) were measured. The doses of the SIM-NOF were adjusted to maintain blood cyclosporine trough levels at 50-180 μg/ml. On cyclosporine profiling, SIN-NOF showed a predictable and constant absorption profile peaking at two hours in all instances with steady declining levels through the following ten hours. With SIM the levels were unpredictable and erratic. The Tmax for SIM-NOF was 2.0± 0 hours and for SIM 3.7± 1.7 hours (p<0.0001). The Cmax for SIM- NOF was 2149 and for SIM 1942 (p=0.008). The 12-hour trough studies for SIM-NOF is a superior preparation to SIM in clinical practice. No specific adverse effects were observed.
  1,997 329 -
Ramdionuclide Assessment of Patients with Urinary Tract Infection and Vesico-ureteric Reflux Using Tc-99m-Dimercaptosuccinic Acid
Hussan Al-Kaylani
January-March 1999, 10(1):70-70
  1,244 240 -
Salt and hypertension in Man
PT Subramanian
January-March 1999, 10(1):69-69
  1,035 251 -
  My Preferences